title: Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.
abstract: Cyclosporine has been in worldwide use for 15 years for patients who have undergone transplantation operations and is now being used to control inflammatory reactions in other organs (eg, joints, bowel, and skin). Neoral, a more consistently absorbed form of cyclosporine, has recently been approved by the Food and Drug Administration for the treatment of psoriasis. This report outlines the indications, contraindications, dosage recommendations, monitoring requirements, adverse events, drug interactions, interactions with other psoriasis treatments, and suggestions for cyclosporine's use in rotational therapy.
authors.affiliation: Department of Dermatology at the Mount Sinai School of Medicine, New York, New York 10029-6574, USA.
authors.forename: M
authors.initials: M
authors.lastname: Lebwohl
authors.forename: C
authors.initials: C
authors.lastname: Ellis
authors.forename: A
authors.initials: A
authors.lastname: Gottlieb
authors.forename: J
authors.initials: J
authors.lastname: Koo
authors.forename: G
authors.initials: G
authors.lastname: Krueger
authors.forename: K
authors.initials: K
authors.lastname: Linden
authors.forename: J
authors.initials: J
authors.lastname: Shupack
authors.forename: G
authors.initials: G
authors.lastname: Weinstein
mesh_terms: D000075202:Contraindications; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine